ClinicalTrialsFinder
RecruitingPhase 2Phase 3NCT07589244

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

A Multicenter, Open-label Phase II/III Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy

Sponsor

Guangzhou Virotech Pharmaceutical Co., Ltd.

Enrollment

66 participants

Start Date

May 13, 2026

Study Type

INTERVENTIONAL

Conditions

HCC

Summary

This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

  • Voluntarily sign the informed consent form (ICF), understand the nature of this study, and agree to comply with and complete all required study procedures.
  • Be aged between 18 and 75 years (inclusive) on the date of signing the ICF, regardless of gender.
  • Have a histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC), or a clinical diagnosis of advanced HCC according to the Standard for Diagnosis and Treatment of Primary Liver Cancer(2024 Edition).
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Have an anticipated life expectancy of ≥ 3 months.
  • Have no severe hematologic, hepatic, renal, coagulation, or cardiac function abnormalities.

Exclusion Criteria4

  • Prior receipt of camrelizumab, apatinib, oncolytic viruses, or other gene therapies.
  • Receipt of other unapproved investigational drugs/devices within 4 weeks or 5 half-lives (whichever is shorter) prior to first dose administration in this study, or immunocompromised status.
  • History of splenectomy.
  • Pregnant or breastfeeding women.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVRT106

VRT106,Intravenous infusion

DRUGVRT106 in combination with camrelizumab and apatinib

VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration

DRUGInvestigator's Choice of Standard of Care

At the investigator's discretion

Locations(1)

The Third Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07589244

Related Trials

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT0591926433 locations

SBRT in HCC With Oligoprogression on First-line Immunotherapy

NCT064344801 location

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT0558100441 locations

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT044727671 location

Optimizing Y90 Therapy for Radiation Lobectomy

NCT043907242 locations